ЛЕКАРСТВЕННОЕ ЛЕЧЕНИЕ БОЛЬНЫХ РАКОМ ЯИЧНИКОВ ЧАСТЬ 1. ЭФФЕКТИВНОСТЬ РАЗЛИЧНЫХ РЕЖИМОВ ХИМИОТЕРАПИИ 1-Й ЛИНИИ У БОЛЬНЫХ РАКОМ ЯИЧНИКОВ

DOI: https://doi.org/10.29296/25877313-2018-07-05
Номер журнала: 
7
Год издания: 
2018

С.В. Хохлова, д.м.н., ст. науч. сотрудник, отделение химиотерапии, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России (Москва) E-mail: svkhokhlova@mail.ru, Д.Н. Кушлинский, к.м.н., онкогинеколог, отделение инновационной онкологии и гинекологии, ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. В.И. Кулакова» Минздрава России (Москва)

Представлены современные данные зарубежной и отечественной литературы, касающиеся вопросов лекарственного лечения больных раком яичников. Проведен сравнительный анализ различных рандомизированных исследований режимов 1-й и 2-й линий химиотерапии, роль неоадьювантного лекарственного лечения, эффективность паклитаксела при платинорезистентных рецидивах опухоли, а также альтернативные комбинации I линии лечения рака яичников и добавление третьего цитостатика к стандартной начальной терапии. Обсуждается клиническая значимость интраперитонеальной химиотерапии в первичном лечении рака яичников, связь прогноза лекарственного лечения со статусом генов BRCA1/BRCA2 у пациенток.

Ключевые слова: 
рак яичников
лекарственная терапия
режимы
эффективность
прогноз
гены BRCA1/BRCA2

Список литературы: 
  1. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive Surgery for Advaced Ovarian carcinoma During the Platinum Era: A Meta Analysis // J. Clin. Oncol. 2002; 20(5):1248--1259.
  2. Lydiksen L., Jensen-Fangel S., Blaakaer J. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? // Gynecol. Oncol. 2014; 133(3):454-459.
  3. Rosa D.D., Clamp A., Mullamitha S., Ton N.C., Lau S., Byrd L., Clayton R., Slade R.J., Kitchener H.C., Shanks J.H., Wilson G., McVey R., Hasan J., Swindell R., Jayson G.C. The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma // Eur. J. Sur. Oncol. 2006; 32(5):588--591.
  4. Bertelsen K., Jakobsen A., Strøyer J., Nielsen K., Sandberg E., Andersen J.E., Ahrons S., Nyland M., Hjortkjaer Pedersen P., Larsen G., et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA) // Gynecol. Oncol. 1993; 49(1):30-36.
  5. Hakes T.B., Chalas E., Hoskins W.J., Jones W.B., Markman M., Rubin S.C., Chapman D., Almadrones L., Lewis J.L. (Jr.) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma // Gynecol. Oncol. 1992; 45(3):284--289.
  6. Lambert H.E., Rustin G.J., Gregory W.M., Nelstrop A.E. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study // Ann. Oncol. 1997; 8(4):327--333.
  7. Omura G., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., Homesley H.D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study // Cancer. 1986; 57(9):1725--1730.
  8. Aabo K., Adams M., Adnitt P., Alberts D.S., Athanazziou A., Barley V., Bell D.R., Bianchi U., Bolis G., Brady M.F., Brodovsky H.S., Bruckner H., Buyse M., Canetta R., Chylak V., Cohen C.J., Colombo N., Conte P.F., Crowther D., Edmonson J.H., Gennatas C., Gilbey E., Gore M., Guthrie D., Yeap B.Y., et al. Chemotherapy in advanced ovarian cancer: four systematic meta analyses of individual patient data from 37 randomized trials // Advanced Ovarian Cancer Trialists’ Group. Br. J. Cancer. 1998; 78(11):1479--1487.
  9. Levin L., Hryniuk W.M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma // J. Clin. Oncol. 1987; 5(5):756--767.
  10. Misset J.L., Vennin P., Chollet P.H., Pouillart P., Laplaige P.H., Frobert J.L., Castera D., Fabro M., Langlois D., Cortesi E., Lucas V., Gamelin E., Laadem A., Otero J. Multicenter phase II III study of oxaliplatin plus cyclophosphamide vs.cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients // Ann. Oncol. 2001; 12(10):1411--1415.
  11. Стенина М.Б. Химиотерапия первой линии при раке яичников: стандарты и нерешенные вопросы // Практическая онкология. 2000. № 4. С. 25-30 (Stenina M.B. Himioterapiya pervoj linii pri rake yaichnikov: standarty i nereshennye voprosy // Prakticheskaya onkologiya. 2000. № 4. S. 25--30).
  12. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer // N. Engl. Med. 1996; 334(1):1-6.
  13. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., Alvarez R.D., Kucera P.R., Small J.M. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study // J. Clin. Oncol. 2000; 18(1):106--115.
  14. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., Stuart G., Kaye S., Vergote I., Blom R., Grimshaw R., Atkinson R.J., Swenerton K.D., Trope C., Nardi M., Kaern J., Tumolo S., Timmers P., Roy J.A., Lhoas F., Lindvall B., Bacon M., Birt A., Andersen J.E., Zee B., Paul J., Baron B., Pecorelli S. Randomized intergroup trial of cisplatin paclitaxel versus cisplatin cyclophosphamide in women with advanced epithelial ovarian cancer: three year results // J. Natl. Cancer Inst. 2000; 92(9):699--708.
  15. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial // Lancet. 2002; 360(9332):505-515.
  16. Spriggs D.R., Brady M.F., Vaccarello L., Clarke-Pearson D.L., Burger R.A., Mannel R., Boggess J.F., Lee R.B., Hanly M. Phase III randomized trial of intravenous cisplatin plus a 24 or 96 hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study // J. Clin. Oncol. 2007; 25(28):4466--4471.
  17. Bolis G., Scarfone G., Polverino G., Raspagliesi F., Tateo S., Richiardi G., Melpignano M., Franchi M., Mangili G., Presti M., Villa A., Conta E., Guarnerio P., Cipriani S., Parazzini F. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial // J. Clin. Oncol. 2004; 22(4):686--690.
  18. Harano K., Terauchi F., Katsumata N., Takahashi F., Yasuda M., Takakura S., Takano M., Yamamoto Y., Sugiyama T. Quality of life outcomes from a randomized phase III trial of dose dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016) // Ann. Oncol. 2014; 25(1):251--257.
  19. Katsumata N., Yasuda M., Isonishi S., Takahashi F., Michimae H., Kimura E., Aoki D., Jobo T., Kodama S., Terauchi F., Sugiyama T., Ochiai K. Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial // Lancet Oncol. 2013; 14(10):1020--1026.
  20. 20. B., Raspagliesi F., Panici P.B., Cormio G., Sorio R., Cavazzini M.G., Ferrandina G., Breda E., Murgia V., Sacco C., Cinieri S., Salutari V., Ricci C., Pisano C., Greggi S., Lauria R., Lorusso D., Marchetti C., Selvaggi L., Signoriello S., Piccirillo M.C., Di Maio M., Perrone F. Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus 3 weeks in patients with advanced ovarian cancer (MITO 7): a randomized, multicentre, open label, phase 3 trial // Lancet Oncol. 2014; 15(4):396--405.
  21. Clamp A., McNeish I., Dean A., et al. ICON8; A GCIG Phase III Randomised Trial Evaluating Weekly Dose-Dense Chemotherapy Integration In First-line Epithelial Ovarian/fallopian Tube/ Primary Peritoneal Carcinoma Treatment; Results of Primary Progression free Survival Analysis // Ann. Oncol. 2017; 28(Suppl 5):v605-v649.10.1093/annonc/mdx440 (ESMO 2017 Annual Meeting).
  22. Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., Kenter G.G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G.C., Pecorelli S., Reed N.S. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer // N. Engl. J. Med. 2010; 363(10):943--953.
  23. Stoeckle E., Bourdarias L., Guyon F., Croce S., Brouste V., Thomas L., Floquet A. Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo Adjuvant Platinum/Taxane Based Chemotherapy and late Interval Debulking Surgery // Ann. Surg. Oncol. 2014; 21(2):629--636.
  24. Румянцев А.А., Тюляндина А.С., Покатаев И.А., Тюляндин С.А. Спорные вопросы оптимальной тактики хирургического лечения больных распространенным раком яичников // Злокачественные опухоли. 2017. Т. 7. № 3. С. 13-22 (Rumyancev A.A., Tyulyandina A.S., Pokataev I.A., Tyulyandin S.A. Spornye voprosy optimal’noj taktiki hirurgicheskogo lecheniya bol’nyh rasprostranennym rakom yaich-nikov // Zlokachestvennye opuholi. 2017. T. 7. № 3. S. 13--22.).
  25. Seward S.M., Winer I. Primary debulking surgery and neoadjuvant chemotherapy in the threatment of advanced epithelial ovarian carcinoma // Cancer Metastasis Rev. 2015; 34(1):5--10.
  26. Pfisterer J., Weber B., Reuss A., Kimmig R., du Bois A., Wagner U., Bourgeois H., Meier W., Costa S., Blohmer J.U., Lortholary A., Olbricht S., Stähle A., Jackisch C., Hardy-Bessard A.C., Möbus V., Quaas J., Richter B., Schröder W., Geay J.F., Lück H.J., Kuhn W., Meden H., Nitz U., Pujade-Lauraine E. AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO OVAR and GINECO // J. Natl. Cancer Inst. 2006; 98(15):1036--1045.
  27. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., Parkin D., Paul J., Hay A., Kaye S.B. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel carboplatin versus paclitaxel carboplatin as first line chemotherapy for ovarian carcinoma // J. Natl. Cancer Inst. 2004; 96(22):1682--1691.
  28. Pignata S., Scambia G., Ferrandina G., Savarese A., Sorio R., Breda E., Gebbia V., Musso P., Frigerio L., Del Medico P., Lombardi A.V., Febbraro A., Scollo P., Ferro A., Tamberi S., Brandes A., Ravaioli A., Valerio M.R., Aitini E., Natale D., Scaltriti L., Greggi S., Pisano C., Lorusso D., Salutari V., Legge F., Di Maio M., Morabito A., Gallo C., Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first line treatment for patients with ovarian cancer: the MITO 2 randomized phase III trial // J. Clin. Oncol. 2011; 29(27):3628--3635.
  29. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., Colombo N., Fowler J.M., Argenta P.A., De Geest K., Mutch D.G., Burger R.A., Swart A.M., Trimble E.L., Accario-Winslow C., Roth L.M. Evaluation of new platinum based treatment of regimens in advanced stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup // J. Clin. Oncol. 2009; 27(9):1419--1425.
  30. Alberts D.S., Liu P.Y., Hannigan E.V., O’Toole R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer // N. Engl. J. Med. 1996; 335(26):1950--1955.
  31. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer // N. Engl. J. Med. 2006; 354(1):34--43.
  32. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., Wadler S., Sickel J. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group // J. Clin. Oncol. 2001; 19(4):1001--1007.
  33. Fujiwara K. Three ongoing intraperitoneal chemotherapy trials in ovarian cancer // J. Gynecol. Oncol. 2012; 23(2):75--77.
  34. Piccart M.J., Floquet A., Scarfone G., Willemse P.H., Emerich J., Vergote I., Giurgea L., Coens C., Awada A., Vermorken J.B. Intraperitoneal cisplatin versus no further treatment: 8 year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum based intravenous chemotherapy // Int. J. Gynecol. Cancer. 2003; 13(2):196--203.
  35. Varia M.A., Stehman F.B., Bundy B.N., Benda J.A., Clarke-Pearson D.L., Alvarez R.D., Long H.J. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group // J. Clin. Oncol. 2003; 21(15):2849--2855.
  36. Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment // Int. J. Gynecol. Cancer. 2003; 13(3):278--286.
  37. Bolis G., Danese S., Tateo S., Rabaiotti E., D’Agostino G., Merisio C., Scarfone G., Polverino G., Parazzini F. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study // Int. J. Gynecol. Cancer. 2006; 16(1):74--78.
  38. De Placido S., Scambia G., Di Vagno G., Naglieri E., Lombardi A.V., Biamonte R., Marinaccio M., Carteni G., Manzione L., Febbraro A., De Matteis A., Gasparini G., Valerio M.R., Danese S., Perrone F., Lauria R., De Laurentiis M., Greggi S., Gallo C., Pignata S. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with cancer: multicenter Italian Trials in Ovarian Cancer (MITO 1) randomized study // J. Clin. Oncol. 2004; 22(13):2635--2642.
  39. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., Jiang C., Alberts D. Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial // J. Clin. Oncol. 2003; 21(13):2460--2465.
  40. Pecorelli S., Favalli G., Gadducci A., Katsaros D., Panici P.B., Carpi A., Scambia G., Ballardini M., Nanni O., Conte P. Phase Ill trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum based chemotherapy: final results of the After 6 protocol 1 // J. Clin. Oncol. 2009; 27(28):4642--4648.
  41. Berek J.S., Taylor P.T., Gordon A., Cunningham M.J., Finkler N., Orr J. (Jr.), Rivkin S., Schultes B.C., Whiteside T.L., Nicodemus C.F. Randomized, placebo controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer // J. Clin. Oncol. 2004; 22(17): 3507--3516.
  42. Hall G.D., Brown J.M., Coleman R.E., Stead M., Metcalf K.S., Peel K.R., Poole C., Crawford M., Hancock B., Selby P.J., Perren T.J. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study // Br. J. Cancer. 2004; 91(4):621--626.
  43. Verheijen R.H., Massuger L.F., Benigno B.B., Epenetos A.A., Lopes A., Soper J.T., Markowska J., Vyzula R., Jobling T., Stamp G., Spiegel G., Thurston D., Falke T., Lambert J., Seiden M.V. Phase III trial of intraperitoneal therapy with yttrium 90 labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission // J. Clin. Oncol. 2006; 24(4):571--578.
  44. Vergote I.B., Joly F., Katsaros D., Coens C., Reinthaller A., Hall M., Steer C.B., Colombo N., Lesoin A., Casado A., Petru E., Green J., Buck M.,. Ray-Coquard I.L., Ferrero A., Favier L., Reed N., Curve H., Jimeno A., Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin based chemotherapy for ovarian carcinoma: A GCIG and EORTC GCG study // J. Clin. Oncol. 2012; 30(18): LBA5000.
  45. Vergote I.B., Jimeno A., Joly F., Katsaros D., Coens C., Despierre E., Marth C., Hall M., Steer C.B., Colombo N., Lesoin A., Casado A., Reinthaller A., Green J., Buck M., Ray-Coquard I., Ferrero A., Favier L., Reed N.S., Cure H., Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin based chemotherapy for ovarian carcinoma: A GCIG and EORTC GCG study // J. Clin. Oncol. 2014; 32(4):320--326.
  46. Markman M. Maintenance chemotherapy in the management of epithelial ovarian cancer // Cancer Metastasis Rev. 2015; 34(1):11--17.
  47. Максимов С.Я., Имянитов Е.Н., Гусейнов К.Д., Городнова Т.В. Клинические особенности BRCA-позитивного рака яичников // Сибирский онкологический журнал. 2013. Т. 6. № 60. С. 14-19 (Maksimov S.Ya., Imyanitov E.N., Gusejnov K.D., Gorodnova T.V. Klinicheskie osobennosti BRCA-pozitivnogo raka yaichnikov // Sibirskij onkologicheskij zhurnal. 2013. T. 6. № 60. S. 14--19).
  48. Хохлова С.В., Горбунова В.А., Любченко Л.Н., Имянитов Е.Н. BRCA-ассоциированный рак яичников (опыт отделения химиотерапии ФГБУ «РОНЦ им. Н.Н.Блохина» Минздрава России) // Современная онкология. 2016. № 1. С. 37-44 (Hohlova S.V., Gorbunova V.A., Lyubchenko L.N., Imyanitov E.N. BRCA-associirovannyj rak yaichnikov (opyt otdeleniya himioterapii FGBU «RONC im. N.N. Blohina» Minzdrava Rossii).
  49. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., Saigo P.E., Almadrones L.A., Barakat R.R., Brown C.L., Chi D.S., Curtin J.P., Poynor E.A., Hoskins W.J. Clinicopathologic features of BRCA linked and sporadic ovarian cancer // JAMA. 2000; 283(17):2260--2265.
  50. Imyanitov E.N. Ovarian cancer genome // Methods Mol. Biol. 2013; 1049:3--7.
  51. Deng C.X., Brodie S.G. Role of BRCA 1 and its interacting // Bioessays. 2010; 22(8):728-737.
  52. Karami F., Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer // Biomed. Res. Int. 2013; 928-562.
  53. Имянитов, Е.Н. Общие представления о наследственных опухолевых синдромах // Практическая онкология. 2014. Т. 15. № 3. С. 101-106 (Imyanitov, E.N. Obshchie predstavleniya o nasledstvennyh opuholevyh sindromah // Prakticheskaya onkologiya. 2014. T. 15. № 3. S. 101--106).
  54. Bolton K.L., Chenevix-Trench G., Goh C., Sadetzki S., Ramus S.J., Karlan B.Y., Lambrechts D., Despierre E., Barrowdale D., McGuffog L., Healey S., Easton D.F., Sinilnikova O., Benitez J., Garcia M.J., Neuhausen S., Gail M.H., Hartge P., Peock S., Frost D., Evans D.G., Eeles R., Godwin A.K., Daly M.B., Kwong A., Ma E.S., Lazaro C., Blanco I., Montagna M., D’Andrea E., Nicoletto M.O., Johnatty S.E., Kjar S.K., Jensen A., Hogdall E., Goode E.L., Fridley B.L., Loud J.T., Greene M.H., Mai P.L., Chetrit A., Lubin F., Hirsh-Yechezkel G., Glendon G., Andrulis I.L., Toland A.E., Senter L., Gore M.E., Gourley C., Michie C.O., Song H., Tyrer J., Whittemore A.S., McGuire V., Sieh W., Kristoffersson U., Olsson H., Borg A., Levine D.A., Steele L., Beattie M.S., Chan S., Nussbaum R.L., Moysich K.B., Gross J., Cass I., Walsh C., Li A.J., Leuchter R., Gordon O., Garcia-Closas M., Gayther S.A., Chanock S.J., Antoniou A.C., Pharoah P.D. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer // JAMA. 2012; 307(4):382--390.
  55. Yang D., Khan S., Sun Y., Hess K., Shmulevich I., Sood A. K., Zhang W. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer // JAMA. 2011; 306(14):1557--1565.
  56. Zhong Q., Peng H.L., Zhao X., Zhang L., Hwang W.T. Effects of BRCA1 and BRCA2 related Mutations on Ovarian and Breast Cancer Survival: A Meta analysis // Clin. Cancer Res. 2014; 21(1):211--220.
  57. Imyanitov E.N., Moiseyenko V.M. Drug therapy for hereditary cancers // Hered Cancer Clin. Pract. 2011; 9(1):5.
  58. Мамедов В.А., Бахидзе Е.В., Имянитов Е.Н. Оценка эффективности лекарственного лечения у больных раком яичников с различным статусом гена BRCA // Сибирский онкологический журнал. 2009. № S1. С. 129-130 (Mamedov V.A., Bahidze E.V., Imyanitov E.N. Ocenka ehffektivnosti lekarstvennogo lecheniya u bol’nyh rakom yaichnikov s razlichnym statusom gena BRCA // Sibirskij onkologicheskij zhurnal. 2009. № S1. S. 129--130).
  59. Safra T., Rogowski O., Muggia F.M. The effect of germ line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer // Int. J. Gynecol. Cancer. 2014; 24(3):488--495.
  60. Yang D., Khan S., Sun Y., Hess K., Shmulevich I., Sood A.K., Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer // JAMA. 2011; 306(14):1557--1565.
  61. Lesnock J.L., Darcy K.M., Tian C., Deloia J.A., Thrall M.M., Zahn C., Armstrong D.K., Birrer M.J., Krivak T.C. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study // Br. J. Cancer. 2013; 108(6):1231--1237.
  62. Turner N., Tutt A., Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers // Nat Rev Cancer. 2004; 4(10):814--819.
  63. Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C., De Greve J., Lubinski J., Shanley S., Messiou C., A’Hern R., Tutt A., Ashworth A., Stone J., Carmichael J., Schellens J.H., de Bono J.S., Kaye S.B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval // J. Clin. Oncol. 2010; 28(15):2512--2519.
  64. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof- of-concept trial // Lancet. 2010; 376(9737):245--251.
  65. Domchek S.M., Aghajanian C., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmana J., Mitchell G., Fried G., Stemmer S.M., Hubert A., Rosengarten O., Loman N., Robertson J.D., Mann H.., Kaufman B. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy // Gynecol. Oncol. 2016; 140(2):199--203.
  66. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A. Olaparib in patients with recurrent high-grade serous or poor ly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study // Lancet Oncol. 2011; 12(9):852--861.
  67. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Saf-ra T., Matei D., Macpherson E., Watkins C., Carmichael J., Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer // N. Engl. J. Med. 2012; 366(15):1382--1392.
  68. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C.L., Meier W., Shapira-Frommer R., Safra T., Matei D., Fielding A., Spencer S., Dougherty B., Orr M., Hodgson D., Barrett J.C., Matulonis U. Olaparib maintenance therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial // Lancet Oncol. 2014; 15(8):852--861.
  69. Ledermann J.A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Fielding A., Spencer S., Rowe P., Lowe E., Hodgson D., Sovak M.A., Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial // Lancet Oncol. 2016; 17(11):1579--1589.
  70. Sandhu S.K., Schelman W.R., Wilding G., Moreno V., Baird R.D., Miranda S., Hylands L., Riisnaes R., Forster M., Omlin A., Kreischer N., Thway K., Gevensleben H., Sun L., Loughney J., Chatterjee M., Toniatti C., Carpenter C.L., Iannone R., Kaye S.B., de Bono J.S., Wenham R.M. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose- escalation trial // Lancet Oncol. 2013; 14(9):882892.